AU2003260618A1 - Treatment of amyotrophic lateral sclerosis using pgc-1 activity-modulating compounds - Google Patents

Treatment of amyotrophic lateral sclerosis using pgc-1 activity-modulating compounds

Info

Publication number
AU2003260618A1
AU2003260618A1 AU2003260618A AU2003260618A AU2003260618A1 AU 2003260618 A1 AU2003260618 A1 AU 2003260618A1 AU 2003260618 A AU2003260618 A AU 2003260618A AU 2003260618 A AU2003260618 A AU 2003260618A AU 2003260618 A1 AU2003260618 A1 AU 2003260618A1
Authority
AU
Australia
Prior art keywords
pgc
activity
treatment
lateral sclerosis
amyotrophic lateral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003260618A
Other versions
AU2003260618A8 (en
Inventor
Annelies Resink
Fabien Schweighoffer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ExonHit Therapeutics SA
Original Assignee
ExonHit Therapeutics SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0207783A external-priority patent/FR2841141A1/en
Application filed by ExonHit Therapeutics SA filed Critical ExonHit Therapeutics SA
Publication of AU2003260618A1 publication Critical patent/AU2003260618A1/en
Publication of AU2003260618A8 publication Critical patent/AU2003260618A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003260618A 2002-06-24 2003-06-23 Treatment of amyotrophic lateral sclerosis using pgc-1 activity-modulating compounds Abandoned AU2003260618A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR0207783A FR2841141A1 (en) 2002-06-24 2002-06-24 Treatment of amyotrophic lateral sclerosis, especially to increase neuronal survival time, comprises use of PGC1 modulator, e.g. PGC1 synthesis activator, statin or osteopontin inhibitor
FR02/07783 2002-06-24
US39326102P 2002-07-02 2002-07-02
US60/393,261 2002-07-02
PCT/FR2003/001924 WO2004000313A2 (en) 2002-06-24 2003-06-23 Treatment of amyotrophic lateral sclerosis using pgc-1 activity-modulating compounds

Publications (2)

Publication Number Publication Date
AU2003260618A1 true AU2003260618A1 (en) 2004-01-06
AU2003260618A8 AU2003260618A8 (en) 2004-01-06

Family

ID=30001929

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003260618A Abandoned AU2003260618A1 (en) 2002-06-24 2003-06-23 Treatment of amyotrophic lateral sclerosis using pgc-1 activity-modulating compounds

Country Status (2)

Country Link
AU (1) AU2003260618A1 (en)
WO (1) WO2004000313A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2579093A1 (en) * 2004-09-03 2006-03-09 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating pgc-1.alpha. to treat neurological diseases and disorders
WO2011074690A1 (en) * 2009-12-14 2011-06-23 Kyoto University Pharmaceutical composition for prevention and treatment of amyotrophic lateral sclerosis
DK2844256T3 (en) 2012-05-02 2023-03-27 Univ Georgetown Treatment of amyotrophic lateral sclerosis with tyrosine kinase inhibitors
CN113384569A (en) * 2013-09-18 2021-09-14 乔治城大学 Treatment of neurodegenerative diseases with fenofibrate and analogs thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2383592A1 (en) * 1999-03-31 2000-10-05 Curagen Corporation 2384891 acids including open reading frames encoding polypeptides; orfx
AU1763201A (en) * 1999-11-10 2001-06-06 Mitokor Modulation of mitochondrial mass and function for the treatment of diseases and for target and drug discovery

Also Published As

Publication number Publication date
WO2004000313A3 (en) 2004-04-22
WO2004000313A2 (en) 2003-12-31
AU2003260618A8 (en) 2004-01-06

Similar Documents

Publication Publication Date Title
EG24848A (en) Preparation of aminopyrimidine compounds
EP1406875A4 (en) N-heterocyclic inhibitors of tnf-alpha expression
AU2002339348A1 (en) Inhibition of STAT-1
EG23458A (en) Set of elements for assemlying structures
IL156595A0 (en) Therapeutic heterocyclic compounds
GB0305150D0 (en) Use of therapeutic compounds
AU2003299100A1 (en) Pyrimidine compounds as therapeutic agents
AU2002353739A1 (en) Therapeutic compounds
AU2002217071A1 (en) Novel use of polyhydroxy compounds
AU2003260618A1 (en) Treatment of amyotrophic lateral sclerosis using pgc-1 activity-modulating compounds
IL161178A0 (en) MODIFICATIONS OF SOLID 3-sn-PHOSPHOGLYCERIDES
AU2003262141A1 (en) Preperation of desloratatine
EP1409463A4 (en) N-heterocyclic inhibitors of tnf-alpha expression
AU2002366812A1 (en) Hydrogenation of precursors to thiazolidinedione antihyperglycemics
EP1420808A4 (en) Treatment of tuberculosis using immunomodulator compounds
HUP0303895A3 (en) Degradation of epothilones
AU2003299080A1 (en) Surface treatment of concrete
AU2002309243A1 (en) Heterocyclic compounds for therapeutic use
AU2003276123A1 (en) Treatment of uveal melanoma
AU2002245330A1 (en) Inhibition of proteasomes to prevent restenosis
PL356853A1 (en) Application of bacteriphages
HU0104370D0 (en) Honeyed schnaps of oerseg
TW459847U (en) Structure of anti-quake fastening piece for stone
AU2003246752A1 (en) Use of densin-like compounds
AU2002255448A1 (en) Treatment of tuberculosis using immunomodulator compounds

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase